Drug Profile
High-affinity CD16-expressing natural killer cell therapy - ImmunityBio
Alternative Names: CD-16 NK-92 cells; haNK; High affinity natural killer cells - ImmunityBio; NK-92 [CD16.158V, ER IL-2]Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator NantKwest
- Developer ImmunityBio
- Class Antineoplastics; Cell adhesion molecules; Cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Merkel cell carcinoma
- Phase I/II Colorectal cancer; Liver cancer; Pancreatic cancer; Squamous cell cancer; Triple negative breast cancer
- No development reported Head and neck cancer; HER2 positive breast cancer; Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for clinical-Phase-Unknown development in Head-and-neck-cancer(Refractory metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 08 Oct 2021 ImmunityBio terminates a phase II QUILT-3.063 trial in Merkel cell carcinoma (Combination therapy, Second line therapy or greater) in USA (NCT03853317)
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio